Arbaclofen in Children and Adolescents with Autism Spectrum Disorder episode artwork

EPISODE · May 12, 2017 · 9 MIN

Arbaclofen in Children and Adolescents with Autism Spectrum Disorder

from NPP BrainPod

Autism Spectrum Disorder is a disorder that has been defined by the medical community, but so far, none of the medications available for ASD treat the core symptoms of the disease, but rather secondary symptoms such as agitation or hyperactivity. Because ASD is genetically linked to Fragile X syndrome, researchers noticed that in a mouse model, the drug arbaclofen reduced what would be core symptoms of autism, such as combatting social avoidance and improving social function. A randomized placebo-controlled trial was conducted to test this idea and the results were recently published in Neuropsychopharmacology. Listen to the latest BrainPod to hear Dr. Jeremy Veenstra-VanderWeele discuss these results! Hosted on Acast. See acast.com/privacy for more information.

Episode metadata supplied by the publisher feed · Published May 12, 2017

Embed this episode

NOW PLAYING

Arbaclofen in Children and Adolescents with Autism Spectrum Disorder

0:00 9:36

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of NPP BrainPod?

This episode is 9 minutes long.

When was this NPP BrainPod episode published?

This episode was published on May 12, 2017.

Can I download this NPP BrainPod episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!